IL312835A - Methods for administering a hemoglobin modulator - Google Patents

Methods for administering a hemoglobin modulator

Info

Publication number
IL312835A
IL312835A IL312835A IL31283524A IL312835A IL 312835 A IL312835 A IL 312835A IL 312835 A IL312835 A IL 312835A IL 31283524 A IL31283524 A IL 31283524A IL 312835 A IL312835 A IL 312835A
Authority
IL
Israel
Prior art keywords
hemoglobin
modulator
administering
methods
Prior art date
Application number
IL312835A
Other languages
English (en)
Hebrew (he)
Inventor
Aline Barth
Ken Duchin
Arthur Lo
Carla B Washington
Original Assignee
Global Blood Therapeutics Inc
Aline Barth
Ken Duchin
Arthur Lo
Carla B Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc, Aline Barth, Ken Duchin, Arthur Lo, Carla B Washington filed Critical Global Blood Therapeutics Inc
Publication of IL312835A publication Critical patent/IL312835A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL312835A 2021-12-10 2022-12-09 Methods for administering a hemoglobin modulator IL312835A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163288377P 2021-12-10 2021-12-10
US202263421524P 2022-11-01 2022-11-01
US202263429376P 2022-12-01 2022-12-01
PCT/US2022/052411 WO2023107697A1 (en) 2021-12-10 2022-12-09 Methods of administering a modulator of hemoglobin

Publications (1)

Publication Number Publication Date
IL312835A true IL312835A (en) 2024-07-01

Family

ID=85108880

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312835A IL312835A (en) 2021-12-10 2022-12-09 Methods for administering a hemoglobin modulator

Country Status (10)

Country Link
US (1) US20250041312A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444285A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024545496A (cg-RX-API-DMAC7.html)
KR (1) KR20240116826A (cg-RX-API-DMAC7.html)
AU (1) AU2022408097B2 (cg-RX-API-DMAC7.html)
CA (1) CA3241881A1 (cg-RX-API-DMAC7.html)
IL (1) IL312835A (cg-RX-API-DMAC7.html)
MX (1) MX2024007064A (cg-RX-API-DMAC7.html)
TW (1) TW202339732A (cg-RX-API-DMAC7.html)
WO (1) WO2023107697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023021606A2 (pt) * 2021-05-14 2023-12-19 Global Blood Therapeutics Inc Formas sólidas de modulador de hemoglobina
EP4727555A1 (en) * 2023-06-13 2026-04-22 Global Blood Therapeutics, Inc. (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
PT3880654T (pt) 2018-11-19 2022-04-08 Global Blood Therapeutics Inc Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina
BR112023021606A2 (pt) * 2021-05-14 2023-12-19 Global Blood Therapeutics Inc Formas sólidas de modulador de hemoglobina

Also Published As

Publication number Publication date
US20250041312A1 (en) 2025-02-06
WO2023107697A1 (en) 2023-06-15
JP2024545496A (ja) 2024-12-09
KR20240116826A (ko) 2024-07-30
CA3241881A1 (en) 2023-06-15
EP4444285A1 (en) 2024-10-16
AU2022408097A1 (en) 2024-05-30
MX2024007064A (es) 2024-06-20
AU2022408097B2 (en) 2026-03-12
TW202339732A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
SG11202104705RA (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
GB2638927B (en) Patient interface
CA228865S (en) Medical syringe
CA228859S (en) Medical syringe
CA210113S (en) Medical syringe
IL285872A (en) Because of the oral administration of an ingestible object to the patient
IL307906A (en) Methods for preparing a hemoglobin modulator
GB202318068D0 (en) Patient interface
IL308541A (en) Uses of somatostatin modulator to treat diseases
CA228477S (en) Medical syringe
CA206768S (en) Part of syringe
EP4126832C0 (en) HEMOGLOBIN MODULATORS
EP4114396A4 (en) Methods of administering elagolix
CA218021S (en) Patient interface
CA203407S (en) Part of syringe
EP3976134A4 (en) Devices and methods for administering a therapeutic preparation
GB202015755D0 (en) Coronavirus therapy
PL3842092T3 (pl) Urządzenie do przezskórnego podawania dwutlenku węgla
CA225227S (en) Patient interface
CA232058S (en) Medical syringe
PL4106840T3 (pl) Urządzenia do podawania cieczy medycznych i odpowiednie sposoby
HK40100684A (en) Intravenous arterial compliance restoration
CA206769S (en) Part of syringe
HK40112608A (en) Uses of a somatostatin modulator for the treatment of disease
AU2021903059A0 (en) Patient interface for promoting natural breathing